S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial

BACKGROUND: We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of metastatic colorectal cancer. METHODS: This trial was a randomized, two-arm...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seung Tae, Hong, Yong Sang, Lim, Ho Yeong, Lee, Jeeyun, Kim, Tae Won, Kim, Kyu-Pyo, Kim, Sun Young, Baek, Ji Yeon, Kim, Jee Hyun, Lee, Keun-Wook, Chung, Ik-Joo, Cho, Sang-Hee, Lee, Kyung Hee, Shin, Sang Joon, Kang, Hye Jin, Shin, Dong Bok, Lee, Jae Won, Jo, Sook Jung, Park, Young Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289339/
https://www.ncbi.nlm.nih.gov/pubmed/25424120
http://dx.doi.org/10.1186/1471-2407-14-883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289339/
https://www.ncbi.nlm.nih.gov/pubmed/25424120
http://dx.doi.org/10.1186/1471-2407-14-883

Ejemplares similares